Funding from the EU, the Federal Republic of Germany and the federal state of Lower Saxony

This project is funded by the European Regional Development Fund.

At ReliaTech, the quality and activity of the cytokines, soluble receptors and antibodies we produce have always been our top priority. To further enhance our quality standards, we are constantly on the lookout for new methods to ensure we can offer our customers the very best quality. That is why we aim to determine and characterise the interactions between molecules, their stability and batch-to-batch consistency with even greater precision.

The aim is to introduce the Thermal Shift Assay to improve the stability testing, activity testing and purity determination of our molecules.

Tax incentives for research and development under the Research Allowance Act (FZulG)

A biotechnological production process based on human (HEK293) cells has been developed for the human glycoprotein holo-transferrin (HTF). To date, HTF has only been purified from human serum or produced in rice cells with a different glycosylation pattern. The use of serum-based proteins is becoming increasingly restricted in the EU and in other European countries. The development of this production process for recombinant HTF represents a major step towards xeno-free culture media. 

The aim is to provide recombinant apo- and holo-transferrin, free from animal-derived components, at a competitive price. This offering is highly attractive to manufacturers of cell culture media and to researchers who prepare their own media. A further advantage is the ability to adjust the required iron loading of the transferrin.

Tax incentives for research and development under the Research Allowance Act (FZulG)

The aim is to develop two monoclonal antibodies: an anti-human liprin beta 1 (PPFIBP1) antibody and an anti-human synemin antibody. There is heterogeneity amongst lymphatic endothelial cells (LECs) in the primary lymphatic vessels, collecting vessels and lymph nodes, and the markers commonly used for LECs do not stain LECs uniformly across all sections of the lymphatic system. In cancer, blood vessels may express LEC markers such as VEGFR3/FLT4, resulting in ‘false-positive’ staining of the blood vessels. Furthermore, heterogeneity in LEC markers has been observed in lymphatic malformations, meaning that LECs cannot be detected in these cases using the antibodies currently available. Additional markers or antibodies against the two molecules PPFIBP1 and synemin for LECs can help to distinguish between blood vessels and lymphatic vessels.

Production of monoclonal antibodies against liprin beta-1 and synemin of high quality and with high binding specificity, enabling LECs to be detected more effectively and accurately.